Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 381

1.

Statins, PCSK9 inhibitors and cholesterol homeostasis: a view from within the hepatocyte.

Sniderman AD, Kiss RS, Reid T, Thanassoulis G, Watts GF.

Clin Sci (Lond). 2017 May 1;131(9):791-797. doi: 10.1042/CS20160872.

PMID:
28424373
2.

Fetal gender and gestational age differentially affect PCSK9 levels in intrauterine growth restriction.

Pecks U, Rath W, Maass N, Berger B, Lueg I, Farrokh A, Farrokh S, Eckmann-Scholz C.

Lipids Health Dis. 2016 Nov 14;15(1):193.

3.

Proprotein convertase subtilisin/kexin type 9 levels and aortic valve calcification: A prospective, cross sectional study.

Wang WG, He YF, Chen YL, Zhao FM, Song YQ, Zhang H, Ma YH, Guan X, Zhang WY, Chen XL, Liu C, Cong HL.

J Int Med Res. 2016 Aug;44(4):865-74. doi: 10.1177/0300060516648030. Epub 2016 Jun 8.

PMID:
27278556
4.

[Modern Lipid therapy today and tomorrow: anti-PCSK9 : A magic bullet concept following Paul Ehrlich].

Erbel R, Gitt AK.

Herz. 2016 Jun;41(4):271-2. doi: 10.1007/s00059-016-4442-4. German. No abstract available.

PMID:
27241696
5.

[Impact of lipid metabolism parameters on the development and progression of coronary artery disease : An update].

Sinning D, Leistner DM, Landmesser U.

Herz. 2016 Jun;41(4):273-80. doi: 10.1007/s00059-016-4430-8. Review. German.

PMID:
27215419
6.

[PCSK9 inhibitors : New treatment option in clinical practice].

Müller-Wieland D, Marx N.

Herz. 2016 Jun;41(4):290-5. doi: 10.1007/s00059-016-4434-4. Review. German.

PMID:
27215418
7.

[PCSK9 - "missing link" in familial hypercholesterolemia : New therapeutic options in hypercholesterolemia and coronary artery disease].

Thiery J, Burkhardt R.

Herz. 2016 Jun;41(4):281-9. doi: 10.1007/s00059-016-4435-3. Review. German.

PMID:
27215417
8.

[PCSK9 inhibitors : Recommendations for patient selection].

Laufs U, Custodis F, Werner C.

Herz. 2016 Jun;41(4):296-306. doi: 10.1007/s00059-016-4429-1. Review. German.

PMID:
27207595
9.

[Introduction of PCSK9 inhibitors : New perspectives in treatment and practical implementation].

Klose G.

Herz. 2016 Jun;41(4):307-12. doi: 10.1007/s00059-016-4428-2. Review. German.

PMID:
27193908
10.

Correlation of serum PCSK9 in CHD patients with the severity of coronary arterial lesions.

Wang S, Cheng ZY, Zhao ZN, Quan XQ, Wei Y, Xia DS, Li JQ, Hu JL.

Eur Rev Med Pharmacol Sci. 2016;20(6):1135-9.

11.

PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study.

Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Boersma E, van Geuns RJ, Serruys PW, Kardys I, Akkerhuis KM.

Atherosclerosis. 2016 May;248:117-22. doi: 10.1016/j.atherosclerosis.2016.03.010. Epub 2016 Mar 11.

PMID:
27015246
12.

Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors.

Leander K, Mälarstig A, Van't Hooft FM, Hyde C, Hellénius ML, Troutt JS, Konrad RJ, Öhrvik J, Hamsten A, de Faire U.

Circulation. 2016 Mar 29;133(13):1230-9. doi: 10.1161/CIRCULATIONAHA.115.018531. Epub 2016 Feb 19.

13.

Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis.

Boyd JH, Fjell CD, Russell JA, Sirounis D, Cirstea MS, Walley KR.

J Innate Immun. 2016;8(2):211-20. doi: 10.1159/000442976. Epub 2016 Jan 13. Review.

PMID:
26756586
14.

Circulating PCSK9 in patients with type 2 diabetes and related metabolic disorders.

Ibarretxe D, Girona J, Plana N, Cabré A, Ferré R, Amigó N, Guaita S, Mallol R, Heras M, Masana L.

Clin Investig Arterioscler. 2016 Mar-Apr;28(2):71-8. doi: 10.1016/j.arteri.2015.11.001. Epub 2015 Dec 29.

PMID:
26743379
15.

Plasma Proprotein Convertase Subtilisin Kexin Type 9 as a Predictor of Carotid Atherosclerosis in Asymptomatic Adults.

Chan DC, Pang J, McQuillan BM, Hung J, Beilby JP, Barrett PH, Watts GF.

Heart Lung Circ. 2016 May;25(5):520-5. doi: 10.1016/j.hlc.2015.10.017. Epub 2015 Nov 18.

PMID:
26706651
16.

Familial hypercholesterolemia: PCSK9 InsLEU genetic variant and prediabetes/diabetes risk.

Saavedra YG, Dufour R, Baass A.

J Clin Lipidol. 2015 Nov-Dec;9(6):786-93.e1. doi: 10.1016/j.jacl.2015.08.005. Epub 2015 Aug 28.

PMID:
26687699
17.

The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis.

Cai G, Zhang B, Shi G, Weng W, Ma C, Song Y, Zhang J.

Lipids Health Dis. 2015 Nov 17;14:149. doi: 10.1186/s12944-015-0154-7.

18.

Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.

Bergeron N, Phan BA, Ding Y, Fong A, Krauss RM.

Circulation. 2015 Oct 27;132(17):1648-66. doi: 10.1161/CIRCULATIONAHA.115.016080. Review.

19.

Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer.

Ozkan C, Akturk M, Altinova AE, Cerit ET, Gulbahar O, Yalcin MM, Cakir N, Balos Toruner F.

Endocr J. 2015;62(12):1091-9. doi: 10.1507/endocrj.EJ15-0308. Epub 2015 Oct 22.

20.

Focus on alirocumab: A PCSK9 antibody to treat hypercholesterolemia.

Devito F, Zito A, Ricci G, Carbonara R, Dentamaro I, Cortese F, Carbonara S, Ciccone MM.

Pharmacol Res. 2015 Dec;102:168-75. doi: 10.1016/j.phrs.2015.09.021. Epub 2015 Oct 8. Review.

PMID:
26455563

Supplemental Content

Support Center